High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Gastroenterology

Volumn 151, Issue 4, 2016, Pages 651-659.e1

  Gane, Edward ^a   Poordad, Fred ^b   Wang, Stanley ^c   Asatryan, Armen ^c   Kwo, Paul Y ^d   Lalezari, Jacob ^e   Wyles, David L ^f   Hassanein, Tarek ^g   Aguilar, Humberto ^h   Maliakkal, Benedict ⁱ   Liu, Ran ^c   Lin, Chih Wei ^c   Ng, Teresa I ^c   Kort, Jens ^c   Mensa, Federico J ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ABBVIE INC   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Quest Clinical Research   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Southern California Liver Centers and Southern California Research Center   (United States)

^h Louisiana Blood Center   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Glecaprevir; Hepatitis C; Pibrentasvir; SURVEYOR

Indexed keywords

GLECAPREVIR; PIBRENTASVIR; PLACEBO; RIBAVIRIN; SOFOSBUVIR; ABT-493; ABT-530; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; ADVERSE DRUG REACTION; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL OUTCOME; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DELUSIONAL DISORDER; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN TISSUE; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NEXT GENERATION SEQUENCING; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCREENING TEST; TREATMENT DURATION; VIRUS RESISTANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; FIBROSIS; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; QUINOXALINES; RIBAVIRIN; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE;

EID: 84989956100     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.07.020     Document Type: Article

References (38)

1. 1 Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385 (2015), 1124–1135.
2. 2 D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006), 217–231.
3. 3 Dienstag, J.L., Ghany, M.G., Morgan, T.R., et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 54 (2011), 396–405.
4. 4 Everson, G.T., Hoefs, J.C., Seeff, L.B., et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 44 (2006), 1675–1684.
5. 5 Hill, A.M., Saleem, J., Heath, K.A., et al. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection. Hepatology 60 (2014), 218–219A.
6. 6 American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org. Accessed: January 29, 2016.
7. 7 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 63 (2015), 199–236.
8. 8 Barua, S., Greenwald, R., Grebely, J., et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
9. 9 Davis, G.L., Alter, M.J., El-Serag, H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521 521 e1-6.
10. 10 Younossi, Z.M., Kanwal, F., Saab, S., et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39 (2014), 518–531.
11. 11 Razavi, H., Waked, I., Sarrazin, C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21:Suppl 1 (2014), 34–59.
12. 12 Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
13. 13 Welzel, T.M., Peterson, J., Ferenci, P., et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program. Hepatology 62 (2015), 225–226A.
14. 14 Hézode, C., de Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology, 62, 2015, 314A.
15. 15 VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. Revised October 2015. North Chicago, IL: AbbVie.
16. 16 ZEPATIER (elbasvir and grazoprevir) tablets, for oral use [package insert]. Revised January 2016. Whitehouse Station, NJ: Merck & Co.
17. 17 HARVONI (ledipasvir and sofosbuvir) tablets [package insert]. Revised March 2015. Foster City, CA: Gilead Sciences.
18. 18 DAKLINZA (daclatasvir) tablets, for oral use [package insert]. Revised July 2015. Princeton, NJ: Bristol-Myers Squibb.
19. 19 OLYSIO (simeprevir) capsules, for oral use [package insert]. Revised October 2015. Titusville, NJ: Johnson & Johnson.
20. 20 Foster, G.R., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
21. 21 Ng T, Krishnan P, Kati W, et al. ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. Available from: http://www.croiconference.org/sites/default/files/posters/639.pdf. Accessed: January 20, 2016.
22. 22 Ng T, Reisch T, Middleton T, et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage. Available from: http://www.croiconference.org/sites/default/files/posters/636.pdf. Accessed: January 20, 2016.
23. 23 Lawitz, E.J., O'Riordan, W.D., Asatryan, A., et al. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother 60 (2015), 1546–1555.
24. 24 Liu, R., Curry, S., McMonagle, P., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59 (2015), 6922–6929.
25. 25 Krishnan, P., Beyer, J., Mistry, N., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59 (2015), 979–987.
26. 26 Cheng, G., Tian, Y., Doehle, B., et al. In vitro antiviral activity and resistance profile characterization of the HCV NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 60 (2016), 1847–1853.
27. 27 Doehle, B.P., Svarovskaia, E.S., Chodavarapu, K., et al. Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/- ribavirin for 12 weeks. J Hepatol 62 (2015), S677–S678.
28. 28 Ng T, Pilot-Matias T, Tripathi R, et al. Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. J Hepatol 2016;64:S409-410.
29. 29 Rower, J.E., Meissner, E.G., Jimmerson, L.C., et al. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother 70 (2015), 2322–2329.
30. 30 Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. J Hepatol 62 (2015), S261–S262.
31. 31 Wang, C., Valera, L., Jia, L., et al. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 57 (2013), 611–613.
32. 32 Foster, G.R., Afdhal, N., Roberts, S.K., Mangia, A., Sulkowski, M., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
33. 33 Cuypers, L., Li, G., Libin, P., et al. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance. Viruses 7 (2015), 5018–5039.
34. 34 Chen, Z.-w., Li, H., Ren, H., et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep, 6, 2016, 20310.
35. 35 Zeuzem S, Mizokami A, Pianko S, et al. Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF. Hepatology 2015;64:254A-255A.
36. 36 Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Presented at American Association for the Study of Liver Diseases, San Francisco, CA, November 13–17, 2015.
37. 37 Kwo PY, Poordad F, Porcalla A, et al. Safety of ABT-493 and ABT-530 co-administered in patients with HCV genotype 1–6 infection: results from the SURVEYOR-I and SURVEYOR-II studies. J Hepatol 2016;64:S809.
38. 38 Kosloski, M.P., Dutta, S., Zhao, W., et al. Pharmacokinetics, safety, and tolerability of next generation direct acting antivirals ABT-493 and ABT-530 in subjects with renal impairment. J Hepatol, 64, 2016, S405.